269 related articles for article (PubMed ID: 30651221)
1. The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma.
Wang M; Wu M; Yang T
EBioMedicine; 2019 Feb; 40():11-12. PubMed ID: 30651221
[No Abstract] [Full Text] [Related]
2. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
Tan W; Luo X; Li W; Zhong J; Cao J; Zhu S; Chen X; Zhou R; Shang C; Chen Y
EBioMedicine; 2019 Feb; 40():446-456. PubMed ID: 30594557
[TBL] [Abstract][Full Text] [Related]
3. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
4. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
5. Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR.
Shao W; Zhu W; Lin J; Luo M; Lin Z; Lu L; Jia H; Qin L; Lu M; Chen J
Neoplasia; 2020 Jan; 22(1):1-9. PubMed ID: 31751859
[TBL] [Abstract][Full Text] [Related]
6. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
Liu G; Kuang S; Cao R; Wang J; Peng Q; Sun C
FASEB J; 2019 Sep; 33(9):10089-10103. PubMed ID: 31199678
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2.
Li C; Wei S; Xu X; Jiang Y; Xue L; Jiang P; Wang J
Int Immunopharmacol; 2019 Nov; 76():105855. PubMed ID: 31472321
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
Streubel G; Schrepfer S; Kallus H; Parnitzke U; Wulff T; Hermann F; Borgmann M; Hamm S
Sci Rep; 2021 May; 11(1):9587. PubMed ID: 33953226
[TBL] [Abstract][Full Text] [Related]
10. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR.
Shao Z; Li Y; Dai W; Jia H; Zhang Y; Jiang Q; Chai Y; Li X; Sun H; Yang R; Cao Y; Feng F; Guo Y
Pharmacol Res; 2018 Sep; 135():188-200. PubMed ID: 30114438
[TBL] [Abstract][Full Text] [Related]
11. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.
Deng YR; Liu WB; Lian ZX; Li X; Hou X
Oncotarget; 2016 Jun; 7(25):38292-38305. PubMed ID: 27203677
[TBL] [Abstract][Full Text] [Related]
13. Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment.
Cheng CC; Chao WT; Liao CC; Tseng YH; Lai YC; Lai YS; Hsu YH; Liu YH
Cell Adh Migr; 2018 Jan; 12(1):19-27. PubMed ID: 28276928
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
15. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.
Chen F; Fang Y; Zhao R; Le J; Zhang B; Huang R; Chen Z; Shao J
Eur J Med Chem; 2019 Oct; 179():916-935. PubMed ID: 31306818
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
[TBL] [Abstract][Full Text] [Related]
17. NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma.
Ma X; Qiu Y; Zhu L; Zhao Y; Lin Y; Ma D; Qin Z; Sun C; Shen X; Li T; Han L
J Mol Med (Berl); 2020 Feb; 98(2):221-232. PubMed ID: 31872284
[TBL] [Abstract][Full Text] [Related]
18. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
19. Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
Hung MH; Tai WT; Shiau CW; Chen KF
World J Gastroenterol; 2014 Nov; 20(41):15269-74. PubMed ID: 25386075
[TBL] [Abstract][Full Text] [Related]
20. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
